At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
TAK-063 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label [^11C]T-773 Positron Emission Tomography Study to Determine Phosphodiesterase10A Occupancy by TAK-063 After a Single Oral Dose in Human Volunteers
In Brief
A Phase 1 clinical trial evaluating TAK-063 and [^11C]T-773 for Healthy Volunteers. Completed, enrolled 13 participants.
Detailed Summary
The purpose of this study is to estimate phosphodiesterase 10A (PDE10A) occupancy in brain following a single dose of TAK-063.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
Primary CompletionFeb 2014
Study CompletionMar 2014
First PostedFeb 2015
TodayJul 2026
First PostedFeb 25, 2015
Enrollment StartOct 1, 2013
Primary CompletionFeb 1, 2014
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.4 years ago
Interventions
TAK-063drug
TAK-063 tablets
[^11C]T-773drug
\[\^11C\]T-773 IV solution